Medical Policy Updates

Notification of Policy Revisions Effective December 31, 2019 (Posted October 15, 2019)

Medical Policy Revision
Urinary Tumor Markers for Bladder Cancer AHS – G2125 "Notification" Medical Director review. Policy statement added that use of quantitative mRNA is considered investigational for all indications. Notification given 10/15/2019 for effective date 12/31/2019.